244 related articles for article (PubMed ID: 12013370)
1. Torsades de pointes associated with fluoroquinolones.
Owens RC; Ambrose PG
Pharmacotherapy; 2002 May; 22(5):663-8; discussion 668-72. PubMed ID: 12013370
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.
Poluzzi E; Raschi E; Motola D; Moretti U; De Ponti F
Drug Saf; 2010 Apr; 33(4):303-14. PubMed ID: 20297862
[TBL] [Abstract][Full Text] [Related]
3. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Frothingham R
Pharmacotherapy; 2001 Dec; 21(12):1468-72. PubMed ID: 11765299
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation with antimicrobial agents: understanding the significance.
Owens RC
Drugs; 2004; 64(10):1091-124. PubMed ID: 15139788
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval.
Iannini PB
Expert Opin Drug Saf; 2002 Jul; 1(2):121-8. PubMed ID: 12904146
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications.
Briasoulis A; Agarwal V; Pierce WJ
Cardiology; 2011; 120(2):103-10. PubMed ID: 22156660
[TBL] [Abstract][Full Text] [Related]
7. Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Tsikouris JP; Peeters MJ; Cox CD; Meyerrose GE; Seifert CF
Ann Noninvasive Electrocardiol; 2006 Jan; 11(1):52-6. PubMed ID: 16472283
[TBL] [Abstract][Full Text] [Related]
8. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Teng C; Walter EA; Gaspar DKS; Obodozie-Ofoegbu OO; Frei CR
Int J Med Sci; 2019; 16(7):1018-1022. PubMed ID: 31341415
[No Abstract] [Full Text] [Related]
9. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review.
Khan F; Ismail M; Khan Q; Ali Z
Expert Opin Drug Saf; 2018 Oct; 17(10):1029-1039. PubMed ID: 30193085
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
[TBL] [Abstract][Full Text] [Related]
11. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
12. Arrhythmias associated with fluoroquinolone therapy.
Falagas ME; Rafailidis PI; Rosmarakis ES
Int J Antimicrob Agents; 2007 Apr; 29(4):374-9. PubMed ID: 17241772
[TBL] [Abstract][Full Text] [Related]
13. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
Amankwa K; Krishnan SC; Tisdale JE
Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes.
Owens RC
Pharmacotherapy; 2001 Mar; 21(3):301-19. PubMed ID: 11253855
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin-induced torsades de pointes.
Sherazi S; DiSalle M; Daubert JP; Shah AH
Cardiol J; 2008; 15(1):71-3. PubMed ID: 18651388
[TBL] [Abstract][Full Text] [Related]
16. Investigation of the potential of clozapine to cause torsade de pointes.
Warner B; Hoffmann P
Adverse Drug React Toxicol Rev; 2002; 21(4):189-203. PubMed ID: 12503253
[TBL] [Abstract][Full Text] [Related]
17. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial-associated QT interval prolongation: pointes of interest.
Owens RC; Nolin TD
Clin Infect Dis; 2006 Dec; 43(12):1603-11. PubMed ID: 17109296
[TBL] [Abstract][Full Text] [Related]
19. Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors.
Bertino JS; Owens RC; Carnes TD; Iannini PB
Clin Infect Dis; 2002 Mar; 34(6):861-3. PubMed ID: 11830802
[TBL] [Abstract][Full Text] [Related]
20. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient.
Gandhi PJ; Menezes PA; Vu HT; Rivera AL; Ramaswamy K
Am J Health Syst Pharm; 2003 Dec; 60(23):2479-83. PubMed ID: 14686224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]